Wockhardt Limited share price
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for r…Read more
HealthcareDrug Manufacturers - Specialty & GenericNifty 500Nifty Smallcap 250NSE: WOCKPHARMAISIN INE049B01025
16 Oct 2026, 3:29 PM IST₹1,954.90▲ 5.50 (0.28%)
- Market Cap₹ 31,766 Cr.
- Current Price₹ 1,954.90
- High / Low₹ 2,422 / 1,087
- Stock P/E77.5
- Book Value₹ 300
- Dividend Yield0.00 %
- ROCE6.4 %
- ROE4.60 %
- Face Value₹ 5.0
More figures (10)
- EPS (TTM)₹ 25.23
- Price / Book6.52
- OPM12.1 %
- Debt / Equity0.45
- Sales growth (5Y)4.5 %
- Profit growth (5Y)-22.0 %
- Promoter holding51.0 %
- EV / EBITDA45.1
- Beta1.00
- All-time high₹ 2,422
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| WOCKPHARMA | -3.29% | +4.18% | +43.84% | +35.17% | +44.11% | +98.74% | +34.50% |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Wockhardt Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹31,766 crore.
- It trades at 77.5 times its last 12 months' earnings and 6.5 times book value.
- Revenue grew 4.5% a year over the last 5 years, profit -22.0% a year.
- Return on equity was 4.6% and return on capital employed 6.4% in the latest year.
- Debt was 0.45 times shareholders' equity.
- The share price is 19.3% below its 52-week high and up 44.1% over one year.
- Promoters and insiders hold about 51.0%; institutions about 13.1%.
Pros
AI- Institutional (FII + DII) holding has risen by 13.2 points over 3 years.
Cons
AI- Return on equity has been low: -3.5% on average over the last 3 years.
- Sales growth has been slow: 4.5% a year over the last 5 years.
- Profit growth has been weak: -22.0% a year over the last 5 years.
- Promoter holding has fallen by 6.06 points over 3 years, to 49.08%.
- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combinat…
- Employees
- 2,564
- Head office
- Mumbai
- NSE industry
- Healthcare
Peer comparison
HealthcareHealthcareDrug Manufacturers - Specialty & Generic
Part ofNifty 500Nifty Smallcap 250
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Wockhardt | 1,954.90 | 77.5 | 31,766 | 0.00 | 107 | — | 929 | 25.88 | 6.4 | 4.6 | 6.52 | 12.1 | 0.45 | 51.02 | 3,373 | 4.5 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 786 | -39.18 | 7,119 | 2.33 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 28,163 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 574 | 29.12 | 4,031 | 12.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 56 Co. | 1,856.85 | 34.1 | 14,445 | 0.21 | 680 | 14.29 | 6,020 | 18.81 | 14.6 | 13.4 | 4.01 | 15.4 | 0.30 | 53.40 | 20,499 | 11.0 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own 3-year sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
- Related Party TransactionsWockhardt Limited has informed the Exchange about related Party Transactions26-May-2023
- Related Party TransactionWockhardt Limited has informed the Exchange about related party transaction for the period ended September 202218-Nov-2022
- Related Party TransactionWockhardt Limited has informed the Exchange about related party transaction for the period ended March 202214-Jun-2022
- Related Party TransactionsWockhardt Limited has informed the Exchange about related Party Transactions17-Jun-2021
- Related Party TransactionsPursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith discl…18-Nov-2020
- Related Party TransactionsWockhardt Limited has informed the Exchange about disclosure of Related Party Transactions on a consolidated basis for the half year ended 31st March, 2020 in the format as prescr…08-Jun-2020
- Related Party TransactionsWockhardt Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI ( LODR) Regulations, 2015. (SEBI Listing Re…02-Dec-2019
- Related Party TransactionsWockhardt Limited has submitted to the Exchange a copy of Disclosure of related party transactions on a consolidated basis for the half year ending 31st March, 2019 pursuant to Re…31-May-2019
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| 3,937 | 4,158 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 | 3,564 | |
| YOY Sales Growth % | 5.63% | -31.61% | -4.77% | 19.26% | -17.93% | 5.55% | 7.65% | 11.99% | ||
| 3,935 | 4,049 | 2,725 | 2,771 | 2,932 | 2,550 | 2,759 | 2,619 | 2,721 | 2,792 | |
| Material Cost % | 46% | 44% | 42% | 42% | 39% | 42% | 42% | 38% | 34% | 33% |
| Employee Cost % | 24% | 23% | 26% | 28% | 23% | 24% | 22% | 22% | 21% | 21% |
| Other Expenses % | 30% | 31% | 27% | 32% | 28% | 30% | 34% | 28% | 26% | 24% |
| Operating Profit | 2 | 110 | 119 | -63 | 298 | 101 | 39 | 393 | 652 | 772 |
| OPM % | 0% | 3% | 4% | -2% | 9% | 4% | 1% | 13% | 19% | 22% |
| 120 | 21 | 39 | 132 | 20 | 122 | 83 | 62 | 111 | 122 | |
| Exceptional items | -358 | -142 | -183 | -294 | -14 | -85 | 12 | |||
| Interest | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 213 | 217 |
| Depreciation | 150 | 166 | 224 | 246 | 247 | 251 | 223 | 217 | 227 | 226 |
| Profit before tax | -641 | -300 | -342 | -568 | -411 | -624 | -420 | -16 | 238 | 463 |
| 16% | 11% | |||||||||
| Current tax | 51 | 9 | -45 | -121 | 38 | 12 | 16 | 7 | 18 | |
| Deferred tax | -25 | -93 | -159 | -151 | -170 | -15 | 36 | 34 | 21 | |
| -667 | -217 | -43 | 689 | -279 | -621 | -472 | -57 | 199 | 414 | |
| Minority share | -59 | -22 | 26 | 3 | -35 | -62 | -9 | -10 | -14 | 5 |
| Profit to shareholders | -608 | -195 | -69 | 686 | -244 | -559 | -463 | -47 | 213 | 409 |
| YOY Profit Growth % | -140.52% | |||||||||
| EPS in Rs | -55.01 | -17.58 | -6.25 | 61.95 | -20.24 | -38.79 | -32.05 | -3.02 | 13.12 | 25.20 |
Compounded Sales Growth
- 5 Years:
- 4%
- 3 Years:
- 8%
- TTM:
- 18%
Compounded Profit Growth
- 5 Years:
- -22%
Stock Price CAGR
- 5 Years:
- 35%
- 3 Years:
- 99%
- 1 Year:
- 44%
Return on Equity
- 4 Years:
- -7%
- Last Year:
- 5%
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2,477 | 2,150 | 890 | 987 | 1,372 | 1,072 | 1,154 | 1,402 | 1,739 | 1,887 | |
| YOY Sales Growth % | -13.21% | -58.60% | 10.92% | 38.97% | -21.87% | 7.65% | 21.49% | 24.04% | ||
| 2,154 | 2,064 | 1,023 | 1,125 | 1,150 | 1,002 | 1,190 | 1,102 | 1,222 | 1,342 | |
| Material Cost % | 39% | 41% | 35% | 42% | 35% | 37% | 40% | 31% | 24% | 25% |
| Employee Cost % | 20% | 22% | 37% | 30% | 19% | 22% | 21% | 19% | 18% | 17% |
| Other Expenses % | 27% | 33% | 43% | 42% | 30% | 34% | 42% | 29% | 28% | 29% |
| Operating Profit | 323 | 86 | -133 | -138 | 222 | 70 | -36 | 300 | 517 | 545 |
| OPM % | 13% | 4% | -15% | -14% | 16% | 7% | -3% | 21% | 30% | 29% |
| 57 | 31 | 43 | 41 | 38 | 67 | 41 | 55 | 137 | 145 | |
| Exceptional items | -142 | -235 | -14 | 25 | 25 | |||||
| Interest | 170 | 171 | 220 | 200 | 273 | 229 | 237 | 199 | 176 | 178 |
| Depreciation | 106 | 122 | 173 | 184 | 171 | 186 | 176 | 168 | 186 | 181 |
| Profit before tax | 104 | -175 | -484 | -624 | -184 | -513 | -422 | -12 | 317 | 356 |
| 34% | ||||||||||
| Current tax | 22 | -47 | -137 | 5 | ||||||
| Deferred tax | 13 | -94 | -111 | -95 | -49 | -47 | ||||
| 69 | -82 | -231 | 593 | -140 | -466 | -422 | -12 | 317 | 356 | |
| YOY Profit Growth % | -219.27% | -123.60% | ||||||||
| EPS in Rs | 6.21 | -7.40 | -20.88 | 53.57 | -11.62 | -32.40 | -29.27 | -0.76 | 19.54 | 21.90 |
Compounded Sales Growth
- 5 Years:
- 12%
- 3 Years:
- 17%
- TTM:
- 29%
Compounded Profit Growth
- 5 Years:
- -12%
- TTM:
- 598%
Stock Price CAGR
- 5 Years:
- 35%
- 3 Years:
- 99%
- 1 Year:
- 44%
Return on Equity
- 4 Years:
- -7%
- Last Year:
- 5%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 72 | 77 | 81 | 81 |
| Reserves | 3,282 | 3,282 | 4,272 | 4,859 |
| 2,184 | 2,356 | 2,021 | 2,233 | |
| Long term borrowings | 224 | 891 | 1,211 | 1,518 |
| Short term borrowings | 1,663 | 1,221 | 648 | 607 |
| 2,145 | 1,934 | 1,761 | 1,442 | |
| Trade payables | 867 | 766 | 592 | 563 |
| Minority interest | 308 | 303 | 304 | 341 |
| Current liabilities | 3,435 | 2,791 | 2,042 | 1,622 |
| Total Liabilities | 7,683 | 7,649 | 8,135 | 8,615 |
| 2,448 | 2,318 | 2,241 | 2,302 | |
| Gross block | 4,650 | 4,694 | 4,837 | 5,164 |
| Accumulated depreciation | 2,202 | 2,376 | 2,596 | 2,862 |
| Goodwill & intangibles | 2,145 | 2,294 | 2,538 | 2,881 |
| CWIP | 426 | 443 | 523 | 684 |
| 4,809 | 4,888 | 5,371 | 5,629 | |
| Inventories | 658 | 640 | 725 | 887 |
| Trade receivables | 797 | 618 | 661 | 588 |
| Cash & equivalents | 90 | 505 | 112 | 217 |
| Current assets | 2,208 | 2,184 | 2,569 | 2,697 |
| Total Assets | 7,683 | 7,649 | 8,135 | 8,615 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 153 | 219 | -22 | 390 | |
| Profit for the year | -559 | -463 | -47 | 213 |
| Working capital changes | 153 | -8 | -492 | -282 |
| Direct taxes paid | -11 | -30 | 31 | -21 |
| -125 | -137 | -783 | -241 | |
| Fixed assets purchased | -209 | -216 | -365 | -364 |
| Fixed assets sold | 79 | 66 | 10 | 50 |
| Investments purchased | -404 | |||
| Investments sold | 39 | |||
| -315 | 334 | 409 | -54 | |
| Proceeds from borrowings | 409 | 549 | 728 | 737 |
| Repayment of borrowings | -406 | -406 | -1,067 | -525 |
| Interest paid | -242 | -197 | -164 | -195 |
| Net Cash Flow | -287 | 416 | -396 | 95 |
| Free Cash Flow | -56 | 3 | -387 | 26 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | -16.7% | -13.8% | -1.2% | 4.6% |
| ROCE | — | -7.8% | -2.7% | 3.9% | 6.4% |
| Operating margin | — | -5.6% | -1.9% | 6.2% | 12.1% |
| Net margin | — | -21.1% | -16.6% | -1.6% | 6.4% |
| Debt / equity | — | 0.65 | 0.70 | 0.46 | 0.45 |
| Current ratio | — | 0.64 | 0.78 | 1.26 | 1.66 |
| Debtor days | — | 110 | 81 | 83 | 65 |
| Inventory days | — | 207 | 192 | 220 | 267 |
| Days payable | — | 273 | 229 | 180 | 169 |
| Cash conversion cycle | — | 44 | 44 | 123 | 163 |
| Working capital days | — | -169 | -79 | 66 | 118 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 49.08%
- FIIs 7.22%
- DIIs 9.24%
- Government 0.02%
- Public 34.44%
| % | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 55.14% | 54.93% | 51.60% | 51.99% | 51.99% | 49.09% | 49.09% | 49.09% | 49.08% | 49.08% | 49.08% | 49.08% |
| 3.02% | 4.17% | 5.49% | 5.93% | 6.70% | 6.54% | 6.81% | 7.29% | 7.10% | 6.99% | 7.09% | 7.22% | |
| Foreign portfolio investors (Cat. I) | 2.84% | 3.96% | 4.91% | 5.30% | 6.09% | 5.94% | 6.28% | 6.59% | 6.52% | 6.41% | 6.46% | 6.45% |
| Foreign portfolio investors (Cat. II) | 0.18% | 0.21% | 0.57% | 0.63% | 0.60% | 0.59% | 0.53% | 0.69% | 0.57% | 0.58% | 0.62% | 0.77% |
| 0.22% | 0.34% | 4.83% | 4.45% | 5.09% | 9.82% | 10.59% | 11.01% | 11.01% | 10.55% | 10.96% | 9.24% | |
| Mutual funds | 0.03% | 0.09% | 3.11% | 2.91% | 2.95% | 7.13% | 7.56% | 8.02% | 7.89% | 7.76% | 8.12% | 6.79% |
| Insurance companies | 0.47% | 0.51% | 0.46% | 0.66% | 0.31% | 0.06% | 0.21% | |||||
| Alternative investment funds | 0.18% | 0.21% | 1.71% | 1.54% | 2.13% | 2.21% | 2.51% | 2.52% | 2.44% | 2.47% | 2.77% | 2.23% |
| Government | 0.01% | 0.01% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.04% | 0.02% | ||
| 41.61% | 40.56% | 38.06% | 37.61% | 36.21% | 34.53% | 33.50% | 32.60% | 32.79% | 33.35% | 32.83% | 34.44% | |
| Retail (up to ₹2 lakh) | 27.12% | 25.45% | 21.85% | 21.78% | 20.80% | 19.64% | 19.09% | 19.03% | 18.66% | 19.06% | 18.87% | 19.47% |
| HNIs (above ₹2 lakh) | 5.77% | 7.49% | 8.08% | 8.40% | 8.22% | 7.85% | 7.61% | 7.01% | 7.44% | 7.46% | 7.03% | 7.84% |
| NRIs | 1.21% | 1.34% | 1.25% | 1.37% | 1.44% | 1.36% | 1.27% | 1.25% | 1.23% | 1.28% | 1.28% | 1.27% |
| Bodies corporate | 5.30% | 4.28% | 4.63% | 3.95% | 3.46% | 3.52% | 3.29% | 3.15% | 2.48% | 2.62% | 2.61% | 2.81% |
| IEPF | 0.16% | 0.16% | 0.20% | 0.20% | 0.20% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.18% |
| No. of Shareholders | 1,72,989 | 1,61,813 | 1,46,138 | 1,40,391 | 1,38,142 | 1,42,710 | 1,41,799 | 1,46,918 | 1,37,946 | 1,42,274 | 1,39,016 | 1,66,518 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Mutual funds & institutions holding Wockhardt
| Holder (above 1%) | Stake |
|---|---|
| Tata Small Cap FundMutual fund | 2.03% |
| HSBC Small Cap FundMutual fund | 1.30% |
| 3P India Equity Fund 1AIF | 1.15% |
As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 6.79% of the company. Shareholders below 1% are not named in the filing.
Documents
Announcements
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed the Certificate received from MUFG Intime India Private Limited, Regis…09-Oct-2026
- Trading WindowWockhardt Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201525-Sep-2026
- Action(s) taken or orders passedIn terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulation…25-Aug-2026
- Copy of Newspaper PublicationPursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the n…25-Aug-2026
- Shareholders meetingDisclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B) Scrutinizers Report on Voting Results of …10-Aug-2026
- Monitoring Agency ReportPursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosur…10-Aug-2026
- Press ReleaseWockhardt Limited has informed the Exchange regarding a press release dated August 10, 2026, titled Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dial…10-Aug-2026
- Press ReleasePursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th…10-Aug-2026
- Outcome of Board MeetingPursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuatio…10-Aug-2026
- Copy of Newspaper PublicationPursuant to Regulation 30 read with Schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, plea…07-Aug-2026
- Shareholders meetingWockhardt Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 202605-Aug-2026
- Copy of Newspaper PublicationPursuant to Regulation 30 read with Schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, plea…18-Jul-2026
Annual reports
- Financial Year 202617-JUL-2026
- Financial Year 202516-JUL-2025
- Financial Year 202406-JUN-2024
- Financial Year 2023
- Financial Year 2022
- Financial Year 2021
- Financial Year 202006-JUL-2020
- Financial Year 201917-JUL-2019
- Financial Year 201805-AUG-2018
- Financial Year 201704-AUG-2017
Credit ratings
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations andDisclosure Requirements) Regulations, 2015, as amended and in continuation to our l…11-Jun-2026
- Investor PresentationWockhardt Limited has informed the Exchange about Investor Presentation04-Jun-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company…01-Jun-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesWockhardt Limited has informed the Exchange about Transcript11-Jun-2025
- Investor PresentationWockhardt Limited has informed the Exchange about Investor Presentation05-Jun-2025
- Investor PresentationWockhardt Limited has informed the Exchange about Investor Presentation05-Jun-2025
- Analysts/Institutional Investor Meet/Con. Call UpdatesWockhardt Limited has informed the Exchange that Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulati…02-Jun-2025
- Analysts/Institutional Investor Meet/Con. Call UpdatesPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform yo…25-Oct-2024
- Analysts/Institutional Investor Meet/Con. Call UpdatesPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform yo…24-Oct-2024
- General UpdatesPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herew…21-Oct-2024
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 17 Nov 2016
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed the Certificate received from MUFG Intime India Private Limited, Regis…NSE filing · 09-Oct-2026
- Trading WindowWockhardt Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 25-Sep-2026
- Action(s) taken or orders passedIn terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulation…NSE filing · 25-Aug-2026
- Copy of Newspaper PublicationPursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the n…NSE filing · 25-Aug-2026
- Shareholders meetingDisclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B) Scrutinizers Report on Voting Results of …NSE filing · 10-Aug-2026
- Monitoring Agency ReportPursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosur…NSE filing · 10-Aug-2026
- Press ReleaseWockhardt Limited has informed the Exchange regarding a press release dated August 10, 2026, titled Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dial…NSE filing · 10-Aug-2026
- Press ReleasePursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th…NSE filing · 10-Aug-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Wockhardt Limited
What is the share price of Wockhardt Limited today?
Wockhardt Limited (WOCKPHARMA) last traded at ₹1,954.90 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.
What is the market cap of Wockhardt Limited?
About ₹31,766 crore at the latest price.
What is the P/E ratio of Wockhardt Limited?
About 77.5 times its earnings over the last 12 months.
Is Wockhardt Limited a good investment?
We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.
How can I buy Wockhardt Limited shares?
You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.
Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).
Talk to us
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Experts are available Mon–Sat, 10 AM – 7 PM
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.